Abstract
Gefitinib(Iressa®) is a newly approved anticancer agent in Japan that acts by inhibiting epidermal growth factor receptor (EGFR) signal transduction.
Gefitinib(Iressa®) was applied to total 32 cases at Department of Internal Medicine, Otemae Hospital. Among 32 cases, 17 cases developed an eruption consinting of acne like erupiton(13,40%), paronychia(7,22%), dry skin on the soles, palms(6,19%), and dry skin on the limbs,trunk(6,19%).
